Printer Friendly

PROCYTE CORPORATION NAMES TWO NEW CORPORATE OFFICERS

 KIRKLAND, Wash., July 7 /PRNewswire/ -- ProCyte Corporation (NASDAQ-NMS: PRCY) announced today the appointment of two new corporate officers: Dr. Michael Dey, vice president, pharmaceutical development and Dr. Ronald Warner, vice president, program management.
 "The additions of Drs. Dey and Warner to ProCyte's senior management team will give ProCyte the additional experience it needs to meet its objective of building a vertically integrated pharmaceutical company and bringing products to market," said Joseph Ashley, ProCyte's president and chief executive officer.
 Dr. Dey will have primary responsibility for pharmaceutical development of ProCyte compounds that have been selected for investigational new drug application status. Dr. Warner, who has been with ProCyte since 1989, directed the company's successful Phase II wound healing studies for its flagship product candidate, Iamin, and will undertake an expanded role to oversee the company's drug commercialization programs.
 "Dr. Dey brings to ProCyte both a technical field of expertise that will significantly benefit the company, as well as industry experience that will augment our ability to optimize the therapeutic applications of our drugs. Dr. Warner will play a vital role in the efficient and successful management of ProCyte's wound healing and inflammatory bowel disease projects, which are proceeding through the clinical development pipeline," said Ashley.
 Dr. Dey received his Ph.D. in pharmacology and toxicology from Washington State University in 1984. Since that time, Dr. Dey has held positions of increasing responsibility at Wyeth-Ayerst laboratories, where, most recently, he directed the research support of Premarin(R), Wyeth-Ayerst's leading drug for its female health franchise. In that role, he served as Wyeth-Ayerst's corporate representative to the Food and Drug Administration (FDA) and the United States Pharmacopea, which establishes standards for drug and drug products. Dr. Dey was also the primary scientific spokesperson at state and federal meetings, including three FDA Advisory Committee Meetings.
 Dr. Warner received his Ph.D. in industrial and physical from Purdue University in 1981 and initially joined ProCyte as the director of pharmaceutical development. Dr. Warner was instrumental in the formation of ProCyte's initial drug development strategy, including drug delivery, quality control and pilot scale manufacturing programs.
 ProCyte Corporation is the leading developer of copper therapeutics for applications in wound healing and tissue repair. In addition to clinical testing for diabetic plantar ulcers, these cost-effective therapeutic agents are being tested for treatment of inflammatory bowel disease and prevention of hair loss.
 -0- 7/7/93
 /CONTACT: Karen L. Hedine, vice president of ProCyte, 206-820-4548/
 (PRCY)


CO: ProCyte Corporation ST: Washington IN: MCT SU: PER

TM -- NY008 -- 8920 07/07/93 08:30 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 7, 1993
Words:425
Previous Article:GZA GEOENVIRONMENTAL TECHNOLOGIES, INC. REPORTS FIRST QUARTER FY '94 RESULTS
Next Article:TRIAD UNVEILS REVOLUTIONARY PRISM AUTOMOTIVE MANAGEMENT SYSTEM
Topics:


Related Articles
PROCYTE ANNOUNCES CONSTRUCTION HAS BEGUN ON REDMOND PLANT
PROCYTE CORP. PLANS STOCK OFFERING
PROCYTE DRUG PREVENTS HAIR LOSS THAT RESULTS FROM CHEMOTHERAPY TREATMENT
PROCYTE REPORTS 1993 FOURTH QUARTER RESULTS
PROCYTE PRESENTS ANTIVIRAL ACTIVITY OF COPPER-BASED DRUGS
PROCYTE COMPLETES PHASE III WOUND HEALING CLINICAL TRIALS
ProCyte Corporation Reports Second Quarter Financial Results
Financial Communications Specialists, Magnum Financial Group, Engaged by ProCyte Corporation.
ProCyte Awarded Additional Patents on Copper Peptide Technology.
ProCyte Corporation Adjourns Special Meeting of Shareholders Until March 18, 2005 to Vote on Merger With PhotoMedex, Inc.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters